CN110339136B - 一种丰韵组合物及其制备方法 - Google Patents
一种丰韵组合物及其制备方法 Download PDFInfo
- Publication number
- CN110339136B CN110339136B CN201910783715.1A CN201910783715A CN110339136B CN 110339136 B CN110339136 B CN 110339136B CN 201910783715 A CN201910783715 A CN 201910783715A CN 110339136 B CN110339136 B CN 110339136B
- Authority
- CN
- China
- Prior art keywords
- extract
- composition
- water
- peg
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title abstract description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 47
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims abstract description 30
- JGUMTYWKIBJSTN-UHFFFAOYSA-N 2-ethylhexyl 4-[[4,6-bis[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 JGUMTYWKIBJSTN-UHFFFAOYSA-N 0.000 claims abstract description 24
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 23
- 244000068988 Glycine max Species 0.000 claims abstract description 23
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims abstract description 23
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims abstract description 23
- 235000008696 isoflavones Nutrition 0.000 claims abstract description 23
- 235000011187 glycerol Nutrition 0.000 claims abstract description 17
- 229940015975 1,2-hexanediol Drugs 0.000 claims abstract description 15
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims abstract description 15
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims abstract description 15
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 15
- 229920002125 Sokalan® Polymers 0.000 claims abstract description 15
- 229960000458 allantoin Drugs 0.000 claims abstract description 15
- 229960001631 carbomer Drugs 0.000 claims abstract description 15
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 15
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 15
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 40
- 238000001816 cooling Methods 0.000 claims description 16
- 238000010438 heat treatment Methods 0.000 claims description 16
- 238000002156 mixing Methods 0.000 claims description 16
- 239000000243 solution Substances 0.000 claims description 16
- 238000003756 stirring Methods 0.000 claims description 16
- 241000554910 Pulsatilla cernua var. koreana Species 0.000 claims description 14
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 14
- 229940098386 usnea barbata extract Drugs 0.000 claims description 13
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 10
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 10
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 9
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims description 9
- 229940013368 zanthoxylum bungeanum fruit extract Drugs 0.000 claims description 9
- MXOAEAUPQDYUQM-QMMMGPOBSA-N (S)-chlorphenesin Chemical compound OC[C@H](O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-QMMMGPOBSA-N 0.000 claims description 8
- FKOKUHFZNIUSLW-UHFFFAOYSA-N 2-Hydroxypropyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(C)O FKOKUHFZNIUSLW-UHFFFAOYSA-N 0.000 claims description 8
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 claims description 8
- 239000004475 Arginine Substances 0.000 claims description 8
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 8
- 241001135917 Vitellaria paradoxa Species 0.000 claims description 8
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims description 8
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 8
- 229960003993 chlorphenesin Drugs 0.000 claims description 8
- DTPCFIHYWYONMD-UHFFFAOYSA-N decaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO DTPCFIHYWYONMD-UHFFFAOYSA-N 0.000 claims description 8
- 239000012895 dilution Substances 0.000 claims description 8
- 238000010790 dilution Methods 0.000 claims description 8
- 238000007599 discharging Methods 0.000 claims description 8
- 230000001804 emulsifying effect Effects 0.000 claims description 8
- 229940100554 isononyl isononanoate Drugs 0.000 claims description 8
- 239000011259 mixed solution Substances 0.000 claims description 8
- -1 polydimethylsiloxane Polymers 0.000 claims description 8
- 238000005086 pumping Methods 0.000 claims description 8
- 229930003799 tocopherol Natural products 0.000 claims description 8
- 229960001295 tocopherol Drugs 0.000 claims description 8
- 239000011732 tocopherol Substances 0.000 claims description 8
- 235000010384 tocopherol Nutrition 0.000 claims description 8
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 8
- 240000007817 Olea europaea Species 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 229940049964 oleate Drugs 0.000 claims description 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 5
- 235000013399 edible fruits Nutrition 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims 1
- 210000000481 breast Anatomy 0.000 abstract description 29
- 230000000694 effects Effects 0.000 abstract description 15
- 230000037394 skin elasticity Effects 0.000 abstract description 6
- 230000000052 comparative effect Effects 0.000 description 15
- 244000046146 Pueraria lobata Species 0.000 description 13
- 235000010575 Pueraria lobata Nutrition 0.000 description 13
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 210000000038 chest Anatomy 0.000 description 6
- 229940057910 shea butter Drugs 0.000 description 6
- 239000006071 cream Substances 0.000 description 5
- 235000003687 soy isoflavones Nutrition 0.000 description 5
- 206010006242 Breast enlargement Diseases 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 229930003427 Vitamin E Natural products 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 229940107131 ginseng root Drugs 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 2
- CCLARULDIPFTCP-BOYHRMMASA-N (2r,3r,4r,5s)-heptane-1,2,3,4,5,6-hexol Chemical compound CC(O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO CCLARULDIPFTCP-BOYHRMMASA-N 0.000 description 2
- 235000002566 Capsicum Nutrition 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 2
- 239000006002 Pepper Substances 0.000 description 2
- 235000016761 Piper aduncum Nutrition 0.000 description 2
- 235000017804 Piper guineense Nutrition 0.000 description 2
- 244000203593 Piper nigrum Species 0.000 description 2
- 235000008184 Piper nigrum Nutrition 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 244000131415 Zanthoxylum piperitum Species 0.000 description 2
- 235000008853 Zanthoxylum piperitum Nutrition 0.000 description 2
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 2
- 230000003416 augmentation Effects 0.000 description 2
- 229940036350 bisabolol Drugs 0.000 description 2
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940008099 dimethicone Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 2
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 2
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 229920001084 poly(chloroprene) Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000007665 sagging Methods 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 206010015995 Eyelid ptosis Diseases 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 241000006302 Usnea Species 0.000 description 1
- 244000089698 Zanthoxylum simulans Species 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 238000005056 compaction Methods 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 229940106579 hops extract Drugs 0.000 description 1
- 239000001906 humulus lupulus l. absolute Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940100460 peg-100 stearate Drugs 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4966—Triazines or their condensed derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/89—Polysiloxanes
- A61K8/891—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9733—Lichens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种丰韵组合物及其制备方法。该组合物组分按照重量百分比包括:甘油2~4%,卡波姆0.15~0.3%,尿囊素0.1~0.2%,丁二醇4~6%,透明质酸钠0.05~0.1%,大豆异黄酮1~2%,葛根提取物1~2%,1,2‑己二醇0.8~1.2%,乙基己基三嗪酮0.8~1.2%,燕麦仁提取物0.8~1.2%。该组合物具有很好的丰胸效果和增加肌肤弹性效果。
Description
技术领域
本发明属于丰胸化妆品及其制备领域,特别涉及一种丰韵组合物及其制备方法。
背景技术
乳房是女性身体的重要部分,乳房的健美对女性至关重要,女性美的体形需要丰满、坚挺的乳房,而乳房扁平偏小、外扩、松弛下垂、左右两边不对称等严重破坏女性的曲线美。目前常用的丰胸方法有:食物丰胸,药物丰胸,化妆品丰胸。化妆品丰胸相对于其他丰胸方法具有明显的特点,不打针、不吃药、不开刀,完全辅助保养品,借助自身肌体的再发育来塑造女性的形体。
例如中国专利CN108295120A公开了一种使乳房丰满美丽的霜剂,该霜剂以重量百分比计包含以下组份:水55%-60%、氢化聚氯丁烯0.5%-2%、甘油三酯2%-.5%、硬脂酸脂8%-15%、丙二醇2%-5.5%、甘油0.5%-2.5%、环聚二甲基硅氧烷2.5%-5.5%、聚二甲基硅氧烷1%-2.5%、人参根提取液3.5%-8.5%、大豆异黄酮提取液3%-5%、葛根提取液2.5%-4.5%、硬脂酸4.5%-8.5%、羟苯甲酯0.05%-0.25%、羟苯乙酯0.01%-0.05%及0.25%-0.55%的甲基葡糖醇聚醚20、6%-8%的啤酒花提取液、0.1%-0.8%的生育酚乙酸脂、0.5%-1%的红没药醇,该霜剂在丰胸的同时能够增加胸部的光彩与弹性,对修复女性胸部产后松弛、乳房变形、胸形不良、外葛根提取液扩下垂、乳房机能减退等问题有非常好的效果。但是该专利需要使用大量大豆异黄酮提取液、葛根提取液、人参根提取液等原料才能有丰胸等效果。
发明内容
本发明所要解决的技术问题是提供一种丰韵组合物及其制备方法,以克服现有技术中丰胸化妆品需要使用大量丰胸原料才能达到丰胸效果等缺陷。
本发明提供一种丰韵组合物,所述组合物组分按照重量百分比包括:甘油2~4%,卡波姆0.15~0.3%,尿囊素0.1~0.2%,丁二醇4~6%,透明质酸钠0.05~1%,大豆异黄酮1~2%,葛根提取物1~2%,1,2-己二醇0.8~1.2%,乙基己基三嗪酮0.8~1.2%,秦椒果提取物0.8~1.2%,须松萝提取物0.8~1.2%,朝鲜白头翁提取物0.8~1.2%,燕麦仁提取物0.8~1.2%,余量的水。
所述组合物组分按照重量百分比还包括:氯苯甘醚0.1~0.2%,异壬酸异壬酯1~3%,辛酸/癸酸甘油三酯1~3%,PEG-75丙二醇硬脂酸酯1~2%,牛油果树果脂油0.5~1%,PEG-10植物甾醇0.4~0.8%,三乙醇胺0.2~0.3%。
所述组合物组分按照重量百分比还包括:生育酚(维生素E)0.2~0.4%,鲸蜡硬脂醇橄榄油酸酯0.2~0.3%,聚二甲基硅氧烷0.2~0.3%,精氨酸0.2~0.3%。
本发明还提供一种丰韵组合物的制备方法,包括:
(1)将甘油2~4%、卡波姆0.15~0.3%、尿囊素0.1~0.2%、氯苯甘醚0.1~0.2%和47.9~72.7%水混合,加热至85℃-90℃;
(2)将异壬酸异壬酯1~3%、辛酸/癸酸甘油三酯1~3%、PEG-75丙二醇硬脂酸酯1~2%、牛油果树果脂油0.5~1%和PEG-10植物甾醇0.4~0.8%混合,加热至85℃-90℃;
(3)将步骤(1)中加热后的混合溶液和步骤(2)中加热后的混合溶液分别抽入乳化锅,真空和搅拌下均质,85℃-90℃保温25~40min,降温;
(4)将透明质酸钠0.05~1%分散于丁二醇4~6%中,加入10~20%水稀释;
(5)步骤(3)中降温至40~45℃,依次加入步骤(4)中稀释后的溶液、大豆异黄酮1~2%、葛根提取物1~2%,1,2-己二醇0.8~1.2%、乙基己基三嗪酮0.8~1.2%、秦椒果提取物0.8~1.2%、须松萝提取物0.8~1.2%、朝鲜白头翁提取物0.8~1.2%、燕麦仁提取物0.8~1.2%、三乙醇胺0.2~0.3%,搅拌20~30min后出料;
步骤(1)-(5)中原料含量均为重量百分比。
本发明还提供一种丰韵组合物的制备方法,包括:
(1)将甘油2~4%、卡波姆0.15~0.3%、尿囊素0.1~0.2%和56.9~76.1%水混合,加热至85℃-90℃;
(2)将生育酚0.2~0.4%、鲸蜡硬脂醇橄榄油酸酯0.2~0.3%、聚二甲基硅氧烷0.2~0.3%和大豆异黄酮1~2%混合,加热至85℃-90℃;
(3)将步骤(1)中加热后的溶液和步骤(2)中加热后的溶液分别抽入乳化锅中,真空和搅拌下均质,85℃-90℃保温25~40min,降温;
(4)将透明质酸钠0.05~1%和精氨酸0.2~0.3%分散于丁二醇4~6%中,加入10~20%水稀释;
(5)步骤(3)中降温至40~45℃,依次加入步骤(4)中稀释后的溶液、葛根提取物1~2%、1,2-己二醇0.8~1.2%、乙基己基三嗪酮0.8~1.2%、秦椒果提取物0.8~1.2%、须松萝提取物0.8~1.2%、朝鲜白头翁提取物0.8~1.2%、燕麦仁提取物0.8~1.2%,搅拌20~30min后出料;
步骤(1)-(5)中原料含量均为重量百分比。
本发明中乙基己基三嗪酮可以促进大豆异黄酮和葛根提取物渗入皮肤,从而使大豆异黄酮和葛根提取物更好的发挥作用,通过补充雌激素激活乳房中的脂肪组织,使流离的脂肪定向吸引到乳房,同时提高皮肤的紧实性和弹性,这三者起到协同丰胸的作用。
有益效果
本发明利用一定含量的大豆异黄酮、葛根提取物和乙基己基三嗪酮协同促进乳腺组织的发育,增加脂肪含量,实现胸部的紧实和挺拔,起到协同丰胸的作用,同时加入燕麦仁提取物可以增加肌肤弹性。
具体实施方式
下面结合具体实施例,进一步阐述本发明。应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围。此外应理解,在阅读了本发明讲授的内容之后,本领域技术人员可以对本发明作各种改动或修改,这些等价形式同样落于本申请所附权利要求书所限定的范围。
实施例1
本实施例提供了一种丰韵组合物,该组合物组分按照重量百分比为:甘油2%,卡波姆0.15%,尿囊素0.1%,氯苯甘醚0.1%,异壬酸异壬酯1%,辛酸/癸酸甘油三酯1%,PEG-75丙二醇硬脂酸酯1%,牛油果树果脂油0.5%,PEG-10植物甾醇0.4%,丁二醇4%,透明质酸钠0.05%,大豆异黄酮1%,葛根提取物1%,1,2-己二醇0.8%,乙基己基三嗪酮0.8%,秦椒果提取物0.8%,须松萝提取物0.8%,朝鲜白头翁提取物0.8%,燕麦仁提取物0.8%,三乙醇胺0.2%,余量的水。
本实施例还提供一种丰韵组合物的制备方法,具体为:
(1)将甘油2%、卡波姆0.15%、尿囊素0.1%、氯苯甘醚0.1%和62.7%水混合,加热至85℃;
(2)将异壬酸异壬酯1%、辛酸/癸酸甘油三酯1%、PEG-75丙二醇硬脂酸酯1%、牛油果树果脂油0.5%和PEG-10植物甾醇0.4%混合,加热至85℃;
(3)将步骤(1)中加热后的混合溶液和步骤(2)中加热后的混合溶液分别抽入乳化锅,开启真空和搅拌,均质5min,85℃-90℃保温25min,降温;
(4)将透明质酸钠0.05%分散于丁二醇4%中,加入20%水稀释;
(5)步骤(3)中降温至40℃,依次加入步骤(4)中稀释后的溶液、大豆异黄酮1%、葛根提取物1%,1,2-己二醇0.8%、乙基己基三嗪酮0.8%、秦椒果提取物0.8%、须松萝提取物0.8%、朝鲜白头翁提取物0.8%、燕麦仁提取物0.8%、三乙醇胺0.2%,搅拌20min后出料;
步骤(1)-(5)中原料含量均为重量百分比。
实施例2
本实施例提供了一种丰韵组合物,该组合物组分按照重量百分比为:甘油3%,卡波姆0.25%,尿囊素0.15%,氯苯甘醚0.15%,异壬酸异壬酯2%,辛酸/癸酸甘油三酯2%,PEG-75丙二醇硬脂酸酯2%,牛油果树果脂油0.5%,PEG-10植物甾醇0.5%,丁二醇6%,透明质酸钠0.07%,大豆异黄酮1.5%,葛根提取物2%,1,2-己二醇1.0%,乙基己基三嗪酮1.2%,秦椒果提取物1.0%,须松萝提取物1.0%,朝鲜白头翁提取物1.0%,燕麦仁提取物1.0%,三乙醇胺0.25%,余量的水。
本实施例还提供一种丰韵组合物的制备方法,具体为:
(1)将甘油3%、卡波姆0.25%、尿囊素0.15%、氯苯甘醚0.15%和63.43%水混合,加热至90℃;
(2)将异壬酸异壬酯2%、辛酸/癸酸甘油三酯2%、PEG-75丙二醇硬脂酸酯2%、牛油果树果脂油0.5%和PEG-10植物甾醇0.5%混合,加热至90℃;
(3)将步骤(1)中加热后的混合溶液和步骤(2)中加热后的混合溶液分别抽入乳化锅,开启真空和搅拌,均质8min,85℃-90℃保温30min,降温;
(4)将透明质酸钠0.07%分散于丁二醇6%中,加入10%水稀释;
(5)步骤(3)中降温至45℃,依次加入步骤(4)中稀释后的溶液、大豆异黄酮1.5%、葛根提取物2%,1,2-己二醇1.0%、乙基己基三嗪酮1.2%、秦椒果提取物1.0%、须松萝提取物1.0%、朝鲜白头翁提取物1.0%、燕麦仁提取物1.0%、三乙醇胺0.25%,搅拌30min后出料;
步骤(1)-(5)中原料含量均为重量百分比。
实施例3
本实施例提供了一种丰韵组合物,该组合物组分按照重量百分比为:甘油2%,卡波姆0.15%,尿囊素0.1%,生育酚(维生素E)0.2%,鲸蜡硬脂醇橄榄油酸酯0.2%,聚二甲基硅氧烷0.2%,丁二醇4%,透明质酸钠0.05%,精氨酸0.2%,大豆异黄酮1%,葛根提取物1%,1,2-己二醇0.8%,乙基己基三嗪酮0.8%,秦椒果提取物0.8%,须松萝提取物0.8%,朝鲜白头翁提取物0.8%,燕麦仁提取物0.8%,余量的水。
本实施例还提供一种丰韵组合物的制备方法,具体为:
(1)将甘油2%、卡波姆0.15%、尿囊素0.1%和66.1%水混合,加热至85℃;
(2)将生育酚0.2%、鲸蜡硬脂醇橄榄油酸酯0.2%、聚二甲基硅氧烷0.2%和大豆异黄酮1%混合,加热至85℃;
(3)将步骤(1)中加热后的溶液和步骤(2)中加热后的溶液分别抽入乳化锅中,开启真空和搅拌,均质5min,85℃-90℃保温30min,降温;
(4)将透明质酸钠0.05%和精氨酸0.2%分散于丁二醇4%中,加入20%水稀释;
(5)步骤(3)中降温至40℃,依次加入步骤(4)中稀释后的溶液、葛根提取物1%、1,2-己二醇0.8%、乙基己基三嗪酮0.8%、秦椒果提取物0.8%、须松萝提取物0.8%、朝鲜白头翁提取物0.8%、燕麦仁提取物0.8%,搅拌20min后出料;
步骤(1)-(5)中原料含量均为重量百分比。
实施例4
本实施例提供了一种丰韵组合物,该组合物组分按照重量百分比为:甘油3%,卡波姆0.18%,尿囊素0.15%,生育酚(维生素E)0.3%,鲸蜡硬脂醇橄榄油酸酯0.25%,聚二甲基硅氧烷0.25%,丁二醇5%,透明质酸钠0.07%,精氨酸0.23%,大豆异黄酮2%,葛根提取物1.8%,1,2-己二醇1%,乙基己基三嗪酮1%,秦椒果提取物1%,须松萝提取物1%,朝鲜白头翁提取物1%,燕麦仁提取物1%,余量的水。
本实施例提供了一种丰韵组合物的制备方法,具体为:
(1)将甘油3%、卡波姆0.18%、尿囊素0.15%和70.77%水混合,加热至90℃;
(2)将生育酚0.3%、鲸蜡硬脂醇橄榄油酸酯0.25%、聚二甲基硅氧烷0.25%和大豆异黄酮2%混合,加热至90℃;
(3)将步骤(1)中加热后的溶液和步骤(2)中加热后的溶液分别抽入乳化锅中,开启真空和搅拌,均质8min,85℃-90℃保温40min,降温;
(4)将透明质酸钠0.07%和精氨酸0.23%分散于丁二醇5%中,加入10%水稀释;
(5)步骤(3)中降温至45℃,依次加入步骤(4)中稀释后的溶液、葛根提取物1.8%、1,2-己二醇1%、乙基己基三嗪酮1%、秦椒果提取物1%、须松萝提取物1%、朝鲜白头翁提取物1%、燕麦仁提取物1%,搅拌30min后出料;
步骤(1)-(5)中原料含量均为重量百分比。
对比例1
根据实施例1,丰韵组合物组分中不添加大豆异黄酮,水的重量百分比改为83.7%,其余均与实施例1相同。
丰韵组合物的制备方法除不添加大豆异黄酮、步骤(1)中水的重量百分比改为63.7%外,其余均与实施例1相同。
对比例2
根据实施例1,丰韵组合物组分中不添加葛根提取物,水的重量百分比改为83.7%,其余均与实施例1相同。
丰韵组合物的制备方法除不添加葛根提取物、步骤(1)中水的重量百分比改为63.7%外,其余均与实施例1相同。
对比例3
根据实施例1,丰韵组合物组分中不添加乙基己基三嗪酮,水的重量百分比改为83.5%,其余均与实施例1相同。
丰韵组合物的制备方法除不添加乙基己基三嗪酮、步骤(1)中水的重量百分比改为63.5%外,其余均与实施例1相同。
对比例4
根据实施例1,丰韵组合物组分中不添加燕麦仁提取物,水的重量百分比改为83.5%,其余均与实施例1相同。
丰韵组合物的制备方法除不添加燕麦仁提取物、步骤(1)中水的重量百分比改为63.5%外,其余均与实施例1相同。
对比例5
根据实施例3,丰韵组合物组分中不添加大豆异黄酮,水的重量百分比改为87.1%,其余均与实施例3相同。
丰韵组合物的制备方法除不添加大豆异黄酮、步骤(1)中水的重量百分比改为67.1%外,其余均与实施例3相同。
对比例6
根据实施例3,丰韵组合物组分中不添加葛根提取物,水的重量百分比改为87.1%,其余均与实施例3相同。
丰韵组合物的制备方法除不添加葛根提取物、步骤(1)中水的重量百分比改为67.1%外,其余均与实施例3相同。
对比例7
根据实施例3,丰韵组合物组分中不添加乙基己基三嗪酮,水的重量百分比改为86.9%,其余均与实施例3相同。
丰韵组合物的制备方法除不添加乙基己基三嗪酮、步骤(1)中水的重量百分比改为66.9%外,其余均与实施例3相同。
对比例8
根据实施例3,丰韵组合物组分中不添加燕麦仁提取物,水的重量百分比改为86.9%,其余均与实施例3相同。
丰韵组合物的制备方法除不添加燕麦仁提取物、步骤(1)中水的重量百分比改为66.9%外,其余均与实施例3相同。
对比例9
根据中国专利CN108295120A,本对比例提供一种使乳房丰满美丽的霜剂,该霜剂以重量百分比计有以下组分:氢化聚氯丁烯0.5%、辛酸/癸酸甘油三酯1%、PEG-100硬脂酸酯8%、丙二醇4%、甘油2%、环聚二甲基硅氧烷3.5%、聚二甲基硅氧烷0.2%、人参根提取液5.5%、大豆异黄酮提取液1%、葛根提取液1%、硬脂酸4.5%、羟苯甲酯0.05%、羟苯乙酯0.01%、啤酒花提取液7%、生育酚乙酸脂0.2%、红没药醇0.5%、甲基葡糖醇聚醚-200.25%以及余量的水。
对实施例1-4以及对比例1-8中丰韵组合物、对比例9中霜剂进行丰胸功效以及皮肤弹性测试。
测试方法为:选取260位年龄30~55岁女性志愿者,都存在胸部偏小,且存在下垂、外扩问题,分为13组,分别使用实施例1-4以及对比例1-8中丰韵组合物、对比例9中霜剂,早晚涂抹产品于胸部表面,轻轻按摩至吸收,连续使用6个月,期间不使用其他产品,使用效果见表1。丰胸功效的评价:胸部更坚实挺拔、明显变大的评价为显效;胸部变大,且下垂、外扩现象得到缓解的评价为有效;胸部没有明显变化的评价为无效。肌肤弹性功效采用打分制,最高分为5分,最低分为1分。
表1
由表1可知,实施例1-4中丰韵组合物的丰胸效果很好,同时肌肤具有很好的弹性。当丰韵组合物中不添加大豆异黄酮、葛根提取物或乙基己基三嗪酮,其丰胸效果显著不佳,说明大豆异黄酮、葛根提取物和乙基己基三嗪酮可以协同增加丰胸效果。当丰韵组合物中不添加燕麦仁提取物,其使肌肤具有弹性的效果降低,说明燕麦仁提取物直接影响了使肌肤具有弹性的功效。对比例9中霜剂虽然含有相同的大豆异黄酮提取液和葛根提取液,但是由于没有加入乙基己基三嗪酮以及其他组分不同,其丰胸功效和使肌肤具有弹性的功效均不佳。
Claims (5)
1.一种丰韵组合物,其特征在于,所述组合物组分按照重量百分比包括:甘油2~4%,卡波姆0.15~0.3%,尿囊素0.1~0.2%,丁二醇4~6%,透明质酸钠0.05~0.1%,大豆异黄酮1~2%,葛根提取物1~2%,1,2-己二醇0.8~1.2%,乙基己基三嗪酮0.8~1.2%,秦椒果提取物0.8~1.2%,须松萝提取物0.8~1.2%,朝鲜白头翁提取物0.8~1.2%,燕麦仁提取物0.8~1.2%,余量的水。
2.根据权利要求1所述组合物,其特征在于,所述组合物组分按照重量百分比还包括:氯苯甘醚0.1~0.2%,异壬酸异壬酯1~3%,辛酸/癸酸甘油三酯1~3%,PEG-75丙二醇硬脂酸酯1~2%,牛油果树果油0.5~1%,PEG-10植物甾醇0.4~0.8%,三乙醇胺0.2~0.3%。
3.根据权利要求1所述组合物,其特征在于,所述组合物组分按照重量百分比还包括:生育酚0.2~0.4%,鲸蜡硬脂醇橄榄油酸酯0.2~0.3%,聚二甲基硅氧烷0.2~0.3%,精氨酸0.2~0.3%。
4.一种丰韵组合物的制备方法,包括:
(1)将甘油2~4%、卡波姆0.15~0.3%、尿囊素0.1~0.2%、氯苯甘醚0.1~0.2%和47.9~72.7%水混合,加热至85℃-90℃;
(2)将异壬酸异壬酯1~3%、辛酸/癸酸甘油三酯1~3%、PEG-75丙二醇硬脂酸酯1~2%、牛油果树果油0.5~1%和PEG-10植物甾醇0.4~0.8%混合,加热至85℃-90℃;
(3)将步骤(1)中加热后的混合溶液和步骤(2)中加热后的混合溶液分别抽入乳化锅,真空和搅拌下均质,85℃-90℃保温25~40min,降温;
(4)将透明质酸钠0.05~0.1%分散于丁二醇4~6%中,加入10~20%水稀释;
(5)步骤(3)中降温至40~45℃,依次加入步骤(4)中稀释后的溶液、大豆异黄酮1~2%、葛根提取物1~2%,1,2-己二醇0.8~1.2%、乙基己基三嗪酮0.8~1.2%、秦椒果提取物0.8~1.2%、须松萝提取物0.8~1.2%、朝鲜白头翁提取物0.8~1.2%、燕麦仁提取物0.8~1.2%、三乙醇胺0.2~0.3%,搅拌20~30min后出料;
步骤(1)-(5)中原料含量均为占丰韵组合物的重量百分比。
5.一种丰韵组合物的制备方法,包括:
(1)将甘油2~4%、卡波姆0.15~0.3%、尿囊素0.1~0.2%和56.9~76.1%水混合,加热至85℃-90℃;
(2)将生育酚0.2~0.4%、鲸蜡硬脂醇橄榄油酸酯0.2~0.3%、聚二甲基硅氧烷0.2~0.3%和大豆异黄酮1~2%混合,加热至85℃-90℃;
(3)将步骤(1)中加热后的溶液和步骤(2)中加热后的溶液分别抽入乳化锅中,真空和搅拌下均质,85℃-90℃保温25~40min,降温;
(4)将透明质酸钠0.05~0.1%和精氨酸0.2~0.3%分散于丁二醇4~6%中,加入10~20%水稀释;
(5)步骤(3)中降温至40~45℃,依次加入步骤(4)中稀释后的溶液、葛根提取物1~2%、1,2-己二醇0.8~1.2%、乙基己基三嗪酮0.8~1.2%、秦椒果提取物0.8~1.2%、须松萝提取物0.8~1.2%、朝鲜白头翁提取物0.8~1.2%、燕麦仁提取物0.8~1.2%,搅拌20~30min后出料;
步骤(1)-(5)中原料含量均为占丰韵组合物的重量百分比。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910783715.1A CN110339136B (zh) | 2019-08-23 | 2019-08-23 | 一种丰韵组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910783715.1A CN110339136B (zh) | 2019-08-23 | 2019-08-23 | 一种丰韵组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110339136A CN110339136A (zh) | 2019-10-18 |
CN110339136B true CN110339136B (zh) | 2022-09-09 |
Family
ID=68181147
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910783715.1A Expired - Fee Related CN110339136B (zh) | 2019-08-23 | 2019-08-23 | 一种丰韵组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110339136B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112274455A (zh) * | 2020-09-25 | 2021-01-29 | 上海森妃日用化学有限公司 | 一种精华水配方及工艺流程 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107157840A (zh) * | 2017-05-25 | 2017-09-15 | 杭州千岛湖蓝色天使实业有限公司 | 一种抗雾霾面霜 |
CN107174547A (zh) * | 2017-05-25 | 2017-09-19 | 杭州千岛湖蓝色天使实业有限公司 | 一种抗雾霾乳液 |
CN108295120A (zh) * | 2017-09-19 | 2018-07-20 | 陈淑珍 | 一种使乳房丰满美丽的霜剂 |
CN108685800A (zh) * | 2018-08-06 | 2018-10-23 | 广州市聚芳企业管理有限公司 | 促雌激素分泌组合物、乳液及其制备方法 |
CN108685743A (zh) * | 2018-08-16 | 2018-10-23 | 余荣华 | 一种丰胸产品的配方 |
CN108785163A (zh) * | 2018-07-03 | 2018-11-13 | 郑州博凯医药保健品有限公司 | 丰胸乳膏及其制备方法和使用方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105919880A (zh) * | 2016-06-13 | 2016-09-07 | 杨海论 | 一种丰胸美乳霜 |
CN109453092A (zh) * | 2019-01-09 | 2019-03-12 | 江西登云健康美业互联有限公司 | 一种有丰胸效果的霜 |
-
2019
- 2019-08-23 CN CN201910783715.1A patent/CN110339136B/zh not_active Expired - Fee Related
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107157840A (zh) * | 2017-05-25 | 2017-09-15 | 杭州千岛湖蓝色天使实业有限公司 | 一种抗雾霾面霜 |
CN107174547A (zh) * | 2017-05-25 | 2017-09-19 | 杭州千岛湖蓝色天使实业有限公司 | 一种抗雾霾乳液 |
CN108295120A (zh) * | 2017-09-19 | 2018-07-20 | 陈淑珍 | 一种使乳房丰满美丽的霜剂 |
CN108785163A (zh) * | 2018-07-03 | 2018-11-13 | 郑州博凯医药保健品有限公司 | 丰胸乳膏及其制备方法和使用方法 |
CN108685800A (zh) * | 2018-08-06 | 2018-10-23 | 广州市聚芳企业管理有限公司 | 促雌激素分泌组合物、乳液及其制备方法 |
CN108685743A (zh) * | 2018-08-16 | 2018-10-23 | 余荣华 | 一种丰胸产品的配方 |
Also Published As
Publication number | Publication date |
---|---|
CN110339136A (zh) | 2019-10-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105411944B (zh) | 油茶花在制备美容护肤产品方面的应用及油茶花面膜膏 | |
CN103340817B (zh) | 一种葛根美白面膜 | |
CN102113987B (zh) | 含天然植物提取物的化妆品及其制备方法 | |
CN105505635B (zh) | 一种含有荷花活性成分的洁肤组合物及其制备方法 | |
CN106726669A (zh) | 一种含有海参多肽的抗衰老化妆品基质及其制备方法 | |
CN104069036B (zh) | 抗衰老化妆品组合物及其制备方法 | |
CN106265478A (zh) | 一种具有丰胸功效的护肤组合物及其应用 | |
CN113318029A (zh) | 一种水润化妆水及其制备方法 | |
CN107847401A (zh) | 防脱发及生发组合物 | |
CN107281053A (zh) | 一种天然洁面慕丝 | |
CN105919880A (zh) | 一种丰胸美乳霜 | |
CN109820175A (zh) | 一种百香果皮膳食纤维和百香果酱及其制备方法 | |
CN110339136B (zh) | 一种丰韵组合物及其制备方法 | |
CN106726895A (zh) | 一种黄花梨护眼霜及其制备方法 | |
CN106176324A (zh) | 一种含有诺丽果精油的美白防晒霜及其制备方法 | |
CN108785163A (zh) | 丰胸乳膏及其制备方法和使用方法 | |
CN105687056B (zh) | 一种适合产妇使用的中药洗发水及其制备方法 | |
CN106916860A (zh) | 一种食药用菌发酵产物的制备方法及其应用 | |
KR20220118660A (ko) | 천연 추출물을 포함하는 미백 화장료 조성물 | |
CN107582461A (zh) | 一种具有丰胸作用的化妆品组合物及乳液 | |
KR101988829B1 (ko) | 여성 가슴 확대 및 피부 탄력 향상용 화장료 조성물 | |
CN105686980B (zh) | 一种滋养舒缓修复眼部精华露 | |
KR102147764B1 (ko) | 피부세포 증식효능이 있는 스핑고리포좀 화장료 조성물 | |
KR101854444B1 (ko) | 아티초크잎 추출물을 유효성분으로 포함하는 튼살 예방 및 개선용 화장료 조성물 | |
CN108135823A (zh) | 包含肌肽、大豆肽及穿心莲提取物的抗老化用组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20220909 |
|
CF01 | Termination of patent right due to non-payment of annual fee |